劲方医药KRAS G12D药物开启一项Ⅲ期临床试验

药渡
Nov 12, 2025

来源:药渡撰文:青晏 编辑:活力哈哈11月11日,药物临床试验登记与信息公示平台显示,劲方医药开启了一项比较GFH375单药与研究者选择化疗治疗KRAS G12D突变型经治转移性胰腺癌患者的有效性及安全性/耐受性的多中心、开放标签、随机对照的III期临床研究。图片来源:药物临床试验登记与信息公示平台RAS基因在约1/3的恶性肿瘤患者中发生突变,其中KRAS突变是恶性肿瘤最常见的功能获得性突变...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10